Phase II Study of Docetaxel (Aisu^Ⓡ) Combined with Three-dimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer

Abstract

Objective: This study was designed to investigate treatment efficacy and side effects of concomitant Aisu ® (docetaxel) with three-dimensional conformal external beam radiotherapy for the treatment of inoperable patients with esophageal cancer. Methods: Inoperable patients were treated with three-dimensional conformal external beam radiotherapy (5/week, 2 GY/day, and total dose 60GY) plus docetaxel (30-45 mg/m 2 , iv, d1, 8). Results: Twenty eight patients met the study eligibility criteria and the response rate was evaluated according to RICIST guidelines. Among 28 patients, 2 achieved CR, 22 PR, 3 SD and 1 patient was documented PD. Mild gastrointestinal reaction and bone marrow suppression were also documented. All treatment related side effects were tolerable. Conclusion: Three-dimensional conformal external beam radiotherapy combined with docetaxel is an active and safe regimen for inoperable patients with esophageal cancer.

What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis

“…However, with the clinical application of more precise radiotherapy techniques such as three-dimensional-conformal or intensity-modulated radiotherapy, the issue of additional dose escalation seems to be of potential value. Many of the studies that investigated the treatment of EC patients successfully administered a total dose of > 50 Gy with decreased treatment-related toxicity [ 26 , 27 ], no excess morbidity [ 28 ] or well tolerated toxicity with concurrent chemotherapy [ 29 – 32 ], even in elderly patients (70∼87 years old) [ 33 ]. Still, many prospective and retrospective studies have evaluated a CCRT dose ≥ 60 Gy in clinical practice.…”

Pre-treatment Metabolic Tumor Volume and Total Lesion Glycolysis are Useful Prognostic Factors for Esophageal Squamous Cell Cancer Patients

“…Three dimension radiotherapy may give more benefit to survival (Shen et al, 2012). But there are many dispute in the radiation dosage and the combined medicine (Cooper et al, 1999).…”

Feasibility and Efficacy of Concurrent Chemoradiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma: a Respective Study of 116 Cases from a Single Institution

“…Fifty-six patients received concomitant chemotherapy: 13 had weekly docetaxel (40 mg̸m²) (Shen et al, 2012), 23 had cisplatin/5-FU (2 cycles with 5-FU 400 mg̸ (m².d) at days 1-5 and cisplatin 20 mg̸ (m².d) at days 1-3) (Mirinezhad et al, 2013), 8 had weekly carboplatin/ paclitaxel (4 courses with carboplatin 20 mg̸ (m 2 .d) and paclitaxel 75 mg/ (m²•d) at day 1), and 12 had doxifluridine (200 mg/d).…”